© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
DiaMedica Therapeutics Inc. (DMAC) stock declined over -1.30%, trading at $5.33 on NASDAQ, down from the previous close of $5.40. The stock opened at $5.48, fluctuating between $5.27 and $5.58 in the recent session.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Employees | 18 |
Beta | 1.46 |
Sales or Revenue | $0.00 |
5Y Sales Change% | -1% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock price is $5.33 in the last trading session. During the trading session, DMAC stock reached the peak price of $5.58 while $5.27 was the lowest point it dropped to. The percentage change in DMAC stock occurred in the recent session was -1.3% while the dollar amount for the price change in DMAC stock was -$0.07.
The NASDAQ listed DMAC is part of Biotechnology industry that operates in the broader Healthcare sector. DiaMedica Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Dietrich John Pauls MBA
Pres, Chief Executive Officer & Director
Dr. Kirsten L. Gruis M.D., M.S.
Chief Medical Officer
Mr. Dominic R. Cundari
Chief Commercial Officer
Mr. Scott B. Kellen C.A.
Chief Financial Officer & Company Sec.
Dr. Edward G. Calamai Ph.D.
Consulting Head of Manufacturing
Ms. Julie VanOrsdel Daves CCRP
Senior Vice President of Clinical Devel. Operations
Mr. David J. Wambeke
Chief Bus. Officer
Ms. Maria Carolina Petrini
Chief Commercial Officer
DMAC's closing price is 149.06% higher than its 52-week low of $2.14 where as its distance from 52-week high of $5.73 is -7.05%.
Number of DMAC employees currently stands at 18.
Official Website of DMAC is: https://www.diamedica.com
DMAC could be contacted at phone 763 612 6755 and can also be accessed through its website. DMAC operates from Two Carlson Parkway, Minneapolis, MN 55447, United States.
DMAC stock volume for the day was 98.26K shares. The average number of DMAC shares traded daily for last 3 months was 83.38K.
The market value of DMAC currently stands at $227.91M with its latest stock price at $5.33 and 42.76M of its shares outstanding.